Rainbow Childrens Medicare Limited — Q3 FY26 earnings call

Call held 29 Jan 2026

Management summary

Rainbow Children's Medicare delivered steady financial performance in Q3 FY26 despite a 'muted' seasonal illness cycle that typically drives higher volumes. The company is transitioning from a heavy capacity-addition phase (780 beds added in two years) to an execution phase focused on operational excellence and occupancy improvement. Management remains confident in achieving a 17-18% revenue CAGR over a four-year period, supported by the ramp-up of new units and a focus on high-end quaternary care like pediatric liver transplants.

Highlights

  • Revenue reported at ₹445.4 crores, representing a 12% YoY growth

  • EBITDA stood at ₹147 crores with a margin of 33%, growing 9% YoY

  • Profit After Tax (PAT) reached ₹73.9 crores, a 7% increase compared to Q3 FY25

  • Occupancy for the quarter was 47.2%, impacted by muted seasonality in mature markets

  • Inpatient discharges and outpatient volumes grew by 9% and 18% respectively

  • Deliveries showed strong momentum with 16% YoY growth

  • Cash position remains robust at ₹579 crores as of December 31, 2025

  • New 100-bed hospital in Rajahmundry reached near-breakeven within three months of commissioning

Key financials

  1. Revenue ₹445.4 Cr +12%YoY
  2. EBITDA ₹147 Cr +9%YoY
  3. EBITDA Margin 33%
  4. PAT ₹73.9 Cr +7%YoY
  5. Occupancy Rate 47.2%
  6. ARPOB ₹60,000

What they filed

Q1 FY27: revenue up 22.7%, net profit up 1.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue404 382 354 335 408 +1%394 +3%408 +15%411 +23%
EBITDA143 130 111 100 141 −1%131 +1%129 +16%115 +15%
Net profit77 67 55 52 73 −5%66 −1%59 +7%53 +2%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Quarterly Revenue
₹33.5 Cr Total
  • Acquired Assets (Guwahati) ₹26.5 Cr 79.1%
  • Acquired Assets (Warangal) ₹7 Cr 20.9%

Guidance & targets

Volume

  • Occupancy Rate Volume · FY27 · High confidence 55-60%
    Our objective is to improve occupancy to around 55%–60%, which is the range where we deliver strong operational and financial outcomes.

    — Ramesh Kancharla, Chairman and Managing Director

Revenue

  • Revenue CAGR Revenue · Next 4 years · Medium confidence 17-18%

    Previously 18-20% → 17-18%

    Over a four-year period, we believe we should be able to achieve around 17-18% CAGR.

    — Ramesh Kancharla, Chairman and Managing Director

  • ARPP Growth Revenue · Long-term · Medium confidence 5-7%
    We expect ARPP to grow at around 5%–7% CAGR over the long term.

    — Vikas Maheshwari, Group CFO

Profitability

  • EBITDA Margin Aspiration Profitability · Long-term · Medium confidence 24-25%
    From a consolidated perspective, our long-term margin aspiration remains around 24% to 25% EBITDA.

    — Ramesh Kancharla, Chairman and Managing Director

  • Bangalore Units EBITDA Loss Profitability · FY26-27 · High confidence ₹12-15 crores
    Yes, INR 12–15 crores would be a prudent assumption [for full-year EBITDA loss for Electronic City and Hennur].

    — Vikas Maheshwari, Group CFO

Risks & concerns

  • Muted Seasonality

    medium

    Lack of seasonal viral illnesses in Q2/Q3 led to lower pediatric outpatient and intensive care admissions.

    Management acknowledged

  • Geopolitical Volatility

    medium

    Conflicts in source markets (Sudan, Bangladesh) have halved international revenue contribution from 4% to 2%.

    Both acknowledged

  • Pricing Pressure from Competition

    medium

    Management claims competitors are 7-10 years behind in specialization, but admits leakage in outpatient footfalls.

    Analyst downplayed

  • Regulatory/Administrative Delays

    low

    Project delays of 9-12 months in some cycles due to government approval processes (e.g., Bangalore zoning changes).

    Management acknowledged

Areas of evasion (2)

  • Geography-wise granular margin details (cited company policy)
  • Specific pricing differential for CGHS empanelment

Q&A highlights

2 direct
Occupancy Growth Strategy Direct
We have significantly strengthened our sales and marketing function... Mr. Abrar Ali has also joined us, which further strengthens execution.

Investors are concerned about low utilization (sub-50%) after massive bed expansion; management is pivoting to a sales-led model to fill capacity.

Asked by Dhananjai Bagrodia, Alchemy Capital

Competition in Mature Markets Partial
Multi-specialty hospitals that earlier lost pediatric and obstetric volumes are now attempting to re-enter mother-and-child care... increased local competition does impact outpatient volumes.

Reveals that while Rainbow dominates high-end care, it is facing 'leakage' in outpatient footfalls to multi-specialty and smaller standalone clinics.

Asked by Anshul Agrawal, Emkay Global

International Business Recovery Direct
We have gradually come back to around 2% of revenue from international business. While we had originally budgeted for about 4%, geopolitical situations significantly impacted some of our key source markets.

Explains the drag on top-line growth from high-margin international patients due to issues in Bangladesh, Sudan, and Kenya.

Asked by Rahul Jeewani, IIFL Capital

1 min read 5 chapters

Detailed narrative

Transition from Expansion to Execution

Rainbow has completed a massive expansion cycle, adding 780 beds over the last two years. Management signaled a shift in focus toward 'operational execution' and filling this new capacity. The company expects a 1.5-year runway without major new capacity additions to focus on driving occupancy from the current 47.2% toward a target of 55-60%.

New Unit Performance and Breakeven Timelines

The Rajahmundry unit has shown exceptional performance, nearing breakeven within just three months of operation. For the new Bangalore units (Electronic City and Hennur), management has budgeted a combined EBITDA loss of ₹12-15 crores for FY26-27. Most units launched in the last two years are expected to be EBITDA positive by next year.

Quaternary Care as a Growth Lever

Rainbow is aggressively scaling its high-end clinical programs to reduce dependence on seasonal illnesses. The pediatric liver transplant program, which started in Hyderabad, has expanded to Chennai and Bangalore. The company aims to perform 100 liver transplants across its network over the next 16-18 months, positioning itself as a leader in complex pediatric surgery.

Digital Transformation and Marketing Pivot

Management admitted that the organization was historically 'doctor-driven' and lacked robust sales and marketing platforms. To counter competition from multi-specialty hospitals, they are revamping their digital stack and appointing senior leadership to drive a 'digital front-door' model. They currently rate their marketing maturity at 30-40% compared to large peers, indicating significant room for improvement.

International Business Headwinds

Geopolitical volatility in key markets like Bangladesh, Sudan, and Kenya has impacted international patient flow. International revenue currently stands at 2%, down from a budgeted 4%. Management is actively diversifying its international strategy to include new, more stable geographies to bring this contribution back to the 4-5% range over time.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls